Sorafenib has been shown to exert anticancer effects both in preclinical models of tumor xenograft (such as breast cancer, colon, and non-small-cell lung) and in vitro by inhibiting TPC1 and TT growth, which carry the RET/PTC1 mutation and C634W RET, respectively [47]. This evidence concerns the gene RET and breast carcinoma.